Abstract:Annexin IV (ANXA4) is highly expressed in ovarian clear cell carcinoma (OCCC); however, its underlying molecular mechanism in OCCC remains unknown. The present study aimed to identify the molecule that ANXA4 may act on and to determine its underlying molecular mechanism. Immunohistochemistry, co-immunoprecipitation and western blotting were performed to detect the expression and interaction of ANXA4, and its associated proteins. Furthermore, MTT assay, flow cytometry, western blotting and gene expression profile enrichment analysis were performed to identify the potential role and molecular mechanism of ANXA4 in OCCC. The results demonstrated that ANXA4 and nuclear factor-kappa-light-chain-enhancer of activated B cells (NF-kappa B) p50 nuclear expression levels were significantly higher in OCCC tissues compared with other subtypes of ovarian cancer, such as serous and mucinous. In addition, a significantly positive correlation was observed between ANXA4 and NF-kappa B p50 expression in OCCC; however, the expression levels of mutant p53 and ANXA4 were negatively correlated in a linear manner. These results suggest that ANXA4 and NF-kappa B p50 may be potential independent risk factors for poor prognosis. ANXA4 and NF-kappa B p50 were demonstrated to interact and their expression was co-localized. The cBioPortal database was used to construct a protein-protein interaction network between ANXA4, NF-kappa B p50 and p53, and functional pathway analysis indicated that the genes were predominantly enriched in the cell cycle and during apoptosis. Transfection of the ANXA4 gene increased the expression of NF-kappa B p50, as well as its downstream targets, Cyclin D1 and B-cell lymphoma-2 (Bcl-2). Furthermore, transfection of the ANXA4 gene increased proliferation and decreased apoptosis of OCCC cells. Treatment with the NF-kappa B inhibitor, BAY 11-7082, decreased Cyclin D1 and Bcl-2 expression levels. Collectively, the results of the present study suggest that wild p53 activates ANXA4 transcription, promotes its expression and enhances NF-kappa B p50 and ANXA4 interaction. This in turn activates the NF-kappa B signaling pathway, promotes cell cycle progression and inhibits apoptosis, thus contributing to the malignant progression of OCCC. Thus, ANXA4 and NF-kappa B p50 may be used as prognostic biomarkers, and may be molecular therapeutic targets in OCCC.

The effects of ANXA2 expression on the surface morphology of Caco2 cells

Annexin A2 Enhances the Progression of Colorectal Cancer and Hepatocarcinoma via Cytoskeleton Structural Rearrangements

ANXA2 enhances the progression of hepatocellular carcinoma via remodeling the cell motility associated structures

Effects of ANXA4 on cell adhesive ability and expression of adhesion-related genes in hepatocellular carcinoma MHCC97H cell line

ANXA2 Silencing Inhibits Proliferation, Invasion, and Migration in Gastric Cancer Cells

[Effects of Annexin A2 gene transcription down-regulation on human hepatoma cell biological behaviour]

Effect of Annexin A1 gene on the proliferation and invasion of esophageal squamous cell carcinoma cells and its regulatory mechanisms

p53 and ANXA4/NF-B p50 complexes regulate cell proliferation, apoptosis and tumor progression in ovarian clear cell carcinoma

Activation of astrocytes by ANXA2-derived extracellular vesicles from lung cancer cells affects aggressiveness, immunotherapy response and microenvironment of lung cancer

Effect of silent CACUL1 expression on the proliferation of esophageal cancer cells and its mechanism

[The Effect and Mechanism of ANXA1 on TPF Chemosensitivity in Oral Squamous Cell Carcinoma].

Anxa5 mediates the in vitro malignant behaviours of murine hepatocarcinoma Hca-F cells with high lymph node metastasis potential preferentially via ERK2/p-ERK2/c-Jun/p-c-Jun(Ser73) and E-cadherin

Clinical significance of Annexin A2 expression in oral squamous cell carcinoma and its influence on cell proliferation, migration and invasion

[Knockdown of lncRNA CACNA1C-AS2 promotes epithelial-mesenchymal transition and enhances the proliferation, invasion and migration of human esophageal cancer cells]

Annexin A2 Promotes the Migration and Invasion of Human Hepatocellular Carcinoma Cells in Vitro by Regulating the Shedding of CD147-Harboring Microvesicles from Tumor Cells

Annexin A5 suppression promotes the progression of cervical cancer

[Expression of Annexin I in Human Pancreatic Cancer and the Influence of Its Down-Regulation on Biology of This Cancer].

LINC00894 targets Annexin A2 to regulate oxaliplatin resistance in hepatocellular carcinoma: ANXA2 protein function

LncRNA MIR155HG induces M2 macrophage polarization and drug resistance of colorectal cancer cells by regulating ANXA2

Roles of N-terminal Annexin A2 phosphorylation sites and miR-206 in colonic adenocarcinoma

Effect of Annexin A1 expression on chemoagents of docetaxel, cisplatin, and 5-fluorouracil for oral squamous cell carcinoma